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Mechanical circulatory support represents an evolving ﬁeld of clinical research and practice. Currently, several
cardiac assist devices have been developed but, among different institutions and countries, a large variation in
indications for use and device selection exists. The Impella platform is an easy to use percutaneous circulatory
support device which is increasingly used worldwide.
During 2014, we established a working group of European physicians who have collected considerable experi-
encewith the Impella device in recent years. By critically comparing the individual experiences and the operative
protocols, this working group attempted to establish the best clinical practice with the technology. The present
paper reviews the main theoretical principles of Impella and provides an up-to-date summary of the best
practical aspects of device use which may help others gain the maximal advantage with Impella technology in
a variety of clinical settings.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Background
The use of percutaneous mechanical support has increased over
the last decade. Given the recent data on the questionable value of
intra-aortic balloon pump (IABP) particularly in acute post-infarction
shock [1–4], leading to a downgrade in the ESC guidelines for routine
use (class III A), an expectation of the possible clinical value of newer
devices which afford greater circulatory support has increased. Among
the most common of these are the extracorporeal systems, either left
atrium to aorta (TandemHeart) or right atrium to aorta (Extracorporeal
Membrane Oxygenation (ECMO)) and the Impella transaortic intraven-
tricular pump. The Impella device was approved in Europe (2005),
Canada (2006), Latin and South America (2008) and recently in China
(2013) for a variety of indications including high risk percutaneous cor-
onary intervention (PCI) and cardiogenic shock. It is estimated that in
the last eight years, over 8000 patients have been supported outside
the United States of America (US). In the US, the device has been used
since 2006 in the Protect I FDA trial for high risk PCI and was granted
510(k) clearance in 2008 [5]. Currently, more than 800 US hospitals
have supported over 20,000 patients.
Although ﬁrst introduced in Europe, there is remarkable variation in
indications for use and type of devices used among different countries
(Fig. 1). The reasons for such disparity may be partially due to different
reimbursement conditions across the region but also uncertainty on
best applications for the various devices in different clinical scenarios.
This working group, whose members jointly represent an experience
of over 1000 European Impella implants, aims to give a state-of-the-
art overview, enabling better understanding of the basic fundamentals
of the Impella technology and application.
2. Impella technical data
Impella technology is based upon aminiaturized axial pump built on
a 9 F catheter. The inlet cage allows for blood to be aspirated from the
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left ventricle (LV) into the cannula portion of the pump and then
expelled above the aortic valve into the ascending aorta. The power con-
nections for the pumpmotor and sensors are contained in the 9 F guid-
ing catheter. The end of the catheter is connected to an external console
which consists of an integrated controller for the pump and purge sys-
tem (Fig. 2) The different Impella catheter models vary in size, insertion
technique and maximum ﬂow capabilities. These pump characteristics
are listed in Table 1.
3. Physiology of Impella support
There are three key physiologic effects of left sided Impella support.
First and foremost, the Impella unloads the left ventricle, reducing LV
end diastolic pressure and LV wall tension and, consequently, decreas-
ing LV work and myocardial oxygen demand [4]. The characteristic
change of the left ventricular pressure volume curve predicted by
computational physiology is shown in Fig. 3 and corresponds well to
physiologic observations.
Secondly, Impella operation results in an increase in mean arterial
pressure, diastolic pressure, cardiac output and thus cardiac power out-
put, leading to improved systemic perfusion and increased coronary
ﬂow. Impella support has been found to improve coronary perfusion
through the combinedmechanism of increased aortic pressure working
synergistically with LV unloading and decreased wall tension [4,6].
Third, Impella leads to a decrease in pulmonary capillary pressure
and a secondary reduction in right ventricular afterload.
4. Impella support and therapeutic effect
Impella technology is load dependent but not rhythm dependent
which leads to a number of physiologic implications. Pump ﬂow is
afterload sensitive in that forward ﬂow through the pump decreases
with increasing ventriculo-aortic pressure gradient. This sensitivity ac-
counts for the characteristic phasic motor current ﬂuctuations during
the cardiac cycle with highest pump ﬂow and motor current achieved
during systole when the gradient between LV and aorta is minimal.
Fig. 1. Geographic distribution of Impella per indication comparing Germany, France, The Netherlands and Italy.
Fig. 2. The Impella (a) Catheter pumps and (b) Automated Impella Controller.
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This characteristic phasic ﬂow pattern is reported as maximum and
minimum ﬂows on the Automated Impella Controller (AIC). The phasic
motor current is also used in the positioning monitoring algorithm and
allows for precise ﬂow calculation. Furthermore, pump ﬂow is preload
dependent because the pump needs sufﬁcient inﬂow for normal
pump output. In patients with acute hemodynamic distress due to left
ventricular failure, preload is normally sufﬁcient for normal pump
action. Yet, extremely impaired inﬂow may be observed in situations
where LV ﬁlling pressure is low, the left ventricular cavity is small or
severe right ventricular function impairment is present. Finally, pump
performance is independent of cardiac rhythm which is a major
distinguishing difference with IABP.
5. Patient selection
Pre-procedural visualization of the LV excluding the presence of
thrombus is advisable when circumstances allow time for cardiac
echo. The most common result of an Impella ingesting a clot in the LV
is that the device will stop. The likelihood of clot ingestion resulting in
embolization of clot is extremely unlikely but amobile thrombus repre-
sents a risk for systemic embolization with any LV catheter placement.
Similarly, severe aortic regurgitation (AR) is a relative contraindica-
tion. A competent valve separating the LV and aorta enables optimal
Impella mediated forward ﬂow. A patient exhibiting decompensating
hemodynamics due to AR will be poorly served by Impella support
since the increased aortic pressure may increase AR and worsen aortic
and LV dilatation.
Peripheral vascular disease is not an absolute contraindication but
its presence and severity should be assessed before insertion of the
device's sheath and Impella catheter implantation attempt. Thus,
depending on the clinical situation, selection of alternative accesses or
pre-implantation peripheral vascular intervention should be considered
before Impella placement in patients with signiﬁcant peripheral artery
disease.
6. High risk intervention
Percutaneous coronary intervention (PCI) can be an alternative
revascularization option for patients in critical conditions that are
refused coronary artery bypass grafting (CABG) due to unacceptably
high risk of complications or death [6]. Nevertheless, these same
patients when undergoing PCI are also exposed to peri-procedural
complications including hemodynamic collapse and potentially lethal
rhythm disturbances. However, timely and effective circulatory support
initiated prior to intervention may allow complex PCI without abrupt
circulatory deterioration during coronary occlusion facilitating more
complete revascularization.
High risk clinical presentation is determined by both the degree of
complexity of the coronary artery disease and clinical co-morbidities
such as LV dysfunction, advanced age, diabetes, renal dysfunction and
prior procedural history. Complex procedures usually require long
procedural times, challenging techniques such as rotational atherecto-
my, and are more prone to acute vessel occlusion, low-ﬂow or distal
embolization, and myocardial necrosis. Extensive stenting may be
required to achieve a good ﬁnal result. The use of Impella support in
high risk interventions has been studied in a prematurely discontinued
randomized controlled trial [7,8] in which at the primary endpoint of
30 day MACE no major difference was observed but at 90 days the
Impella group showed a signiﬁcant reduction in MACE. Also, Impella
support may be a cost effective therapy in the US [9] and EU [10]
compared with IABP counterpulsation. This consensus group is aware
of the current limitation of the available evidence for peri-procedural
mechanical support in planned high-risk PCI but knows from clinical
experience that there are patients that beneﬁt from support in certain
circumstances. Although, there are no evidence based criteria, we
recommend assessing the risk beneﬁt ratio according to some of the
items included in Fig. 4.
7. Cardiogenic shock
Cardiogenic shock (CS) occurs in ~8–10% of patients admitted to
the hospital with ST-elevation myocardial infarction (STEMI). Since
the IABP has shown not to be associated with improved outcome in
CS, more potent devices, such as Impella have been explored and
more recently there is a growing body of (nonrandomized) clinical
data that these devices may improve myocardial function in this
condition [11–15].
The acute and critical decrease in cardiac output (CO) seen in cardio-
genic shock can potentiate myocardial ischemia and cause cell death in
the infarct border zone and in the remote zone. Immediate revasculari-
zation relieves ischemia but does not immediately improve CO or left
ventricular ejection fraction. Inotropic agents and vasoconstrictors
Table 1
Pump characteristics.
Impella 2.5 Impella CP Impella 5.0/LD Impella RP
Access Percutaneous, femoral Percutaneous, femoral Surgical, axillary/fem or ascend aorta Percutaneous, femoral vein
Output (max) 2.5 L/min 4.0 L/min 5.0 L/min 4.6 L/min
Guiding catheter size 9 F 9 F 9 F 11 F
Motor size 12 F 14 F 21 F 22 F
Introducer size 13 F peel away 14 F peel away Dacron graft 10 mm recommended 23 F peel away
RPM (max) 51,000 46,000 33,000 33,000
EU approval 5 days CE Mark 5 days CE Mark 10 days CE Mark 14 days CE Mark
Fig. 3. Pressure–volume loop: Normal conditions (brown), Acute Heart Failure without
hemodynamic support (blue), with Impella CP support (green) and with ECMO support
(red). The loop area is an estimate of the mechanical work performed by the ventricle.
Note the area reduction (work reduction) by the Impella device and the characteristic
oblique vertical lines in the latter, indicating continuous emptying of the ventricle even
in the “isovolumic” phases.
Data from the Basel Heart Simulator Project, P. Hunziker.
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temporarily improve CO and peripheral perfusion but do not interrupt
(and may accelerate) the vicious cycle of decline [16].
Hemodynamic parameters like cardiac power, and stroke work
index have been established as powerful short-term prognostic data
[17]. Nevertheless, there has been a decline in pulmonary artery (PA)
catheter (Swan–Ganz) use likely due to the controversy sparked by a
prospective observational study that suggested that PA catheters were
associated with poor outcome. The authors feel that Swan–Ganz cathe-
terization should be seriously considered to assess the severity of CS
especially when mechanical cardiac assistance devices like Impella are
selected. Of note, the timing of Impella support initiation is a critical
factor in the treatment of refractory cardiogenic shock. Data from the
USpella cohort study reported that in STEMI and NSTEMI CS patients,
initiation of Impella support prior to PCI was associated with improved
survival rates and a higher degree of complete revascularization [11].
This consensus group is aware of the current limitation of the available
evidence for mechanical support in patients with cardiogenic shock
but there is a wide clinical experience with these devices in severe
cardiogenic shock. This consensus group recommends usage of Impella
in cardiogenic shock patients, but not without individual assessment of
risk versus beneﬁt, using some of the criteria depicted in Fig. 5.
8. Impella support for other indications
In addition to its application in high risk PCI and cardiogenic shock
complicating acute myocardial infarction, Impella has been successfully
employed in a wide variety of clinical scenarios requiring percutaneous
left ventricular support.
Among these clinical scenarios, fulminate myocarditis is a setting
where Impella support has been used successfully [13,18] to maintain
cardiac output in the acute phase at a time when ventricular function
decreases profoundly. Successful use in post-cardiotomy cardiogenic
shock (PCCS) has also been reported. In one study, 30-day survival
rates in PCCS patients treated with Impella were comparable to studies
evaluating surgically implanted LVADs [19].
Although severe aortic stenosis is considered a relative contraindica-
tion for Impella support, a growingnumber of investigators have reported
successful and safe use to support high-risk aortic valvuloplasty and PCI
Fig. 4. Patient selection in high-risk PCI.
Fig. 5. Patient selection in cardiogenic shock.
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[20–23]. Further, Impella has been deployed following acute circulatory
collapse post transaortic valve replacement (TAVR) to immediately
support the failing left ventricle [24].
Another growing indication for Impella support is during ablation of
ventricular tachycardia (VT) enabling the procedure to be performed
under relatively stable conditions despite the induction of otherwise
hemodynamically intolerable VT [25–29].
9. Combined Impella use with other devices and escalation of
support
According to the anticipated degree of support needed, the Impella
2.5, Impella CP, or Impella 5.0 may be implanted [19,30,31]. This choice
is centered around both the size of the patient which characterizes the
native hemodynamic “burden” as well as the degree of hemodynamic
compromise. It is important to understand that the pre-insertion native
CO is not simply added to intended Impella ﬂow to obtain a total cardiac
output. The native output will be unloaded with the device pumping at
an optimal target. Thus a patient with a pre-insertion cardiac output of
3 L/min who had an Impella CP placed and pumping 3.5 L/min, would
not be expected to have a total cardiac output of 6.5 L/min. Rather the
patient's native heart would be unloaded to a degree bringing the native
contribution down to, for example, 1.8 L/min resulting in a total “CO” of
5.3 L/min [6]. In patients with profound compromise a large Impella
pump (Impella CP or 5.0) might unload the native LV to the point of
continuous aortic valve closure resulting in a non-pulsatile arterial
curve on the monitor.
Patients in cardiogenic shock may often have both right and left
ventricular compromise [32]. In cases with right ventricular heart fail-
ure (e.g. biventricular failure), acute lung congestion or multi-organ
dysfunction syndrome, several reports have demonstrated combined
use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO)
and Impella [30,33,34]. In cases of severe left ventricular failure,
VA-ECMO increases left ventricular load due to retrograde aortic
blood return via the arterial cannula and therefore may not be able to
decompress the left ventricle, resulting in LV distension and delayed
LV recovery [35]. Combined use with the Impella device unloads the
LV while on ECMO support. Further, the Impella device allows earlier
and expeditious weaning from ECMO. According to our experience
with the combined use of Impella and ECMO support, the performance
level of the Impella device should be reduced to a level that provides
sufﬁcient unloading of the LV and adequate hemodynamic support.
For patients with severe right heart failure, the recently CE approved
percutaneous right ventricular-assist device Impella RP may represent
another valuable option. The Impella RP is currently available in EU
and ﬁrst experiences with the percutaneous right ventricular Impella
are promising especially in patients with RV failure after surgical LVAD
implantation and heart transplantation as well as in post AMI CS includ-
ing its combined use with left sided percutaneous support [36,37].
There have been several clinical reports suggesting the combined
use of Impella with IABP [38,39]. However, this combination decreases
Impella forward ﬂow during diastole due to diastolic pressure augmen-
tation from the IABP. In addition, there are multiple device interactions
leading to misinterpretation of alarms, potential position issues, and
perhaps most importantly, the fact that the IABP induced momentary
ﬂow reductions through the Impella prolong red cell transit times thus
increasing shear stress possibly leading to hemolysis. Since maintaining
adequate forward ﬂow and cardiac output in order to perfuse vital
organs is essential in cardiogenic shock and consistent with the
manufacturer's recommendations,we do not recommend the systematic
simultaneous use of the Impella device with an IABP.
10. Access site management
Meticulous attention should be paid to the selection andmanagement
of the access site for Impella support in order to reduce complications
seen with larger sheaths [40].
When Impella implantation is planned in an elective situation, the
access site selection and the implantation/removal technique should
take into account the patient's anatomy and the operator's experience.
Percutaneous insertion through the common femoral artery is highly
advisable for the Impella 2.5 and CP, whereas axillary artery access is
preferred for the Impella 5.0 (via surgical technique). The suitability of
the arterial access can be easily screened by angiographic assessment.
While closure devices such as Perclose have been successfully used
with Impella, longer term implants for several days should not be
treated with percutaneous preclosure techniques due to infection risk.
Arterial ﬂow disruption can be avoided by removal of the peel away
sheath and use of the repositioning sheath on the Impella catheter.
Manual compression is almost always sufﬁcient but direct surgical
closure may also be considered. Although rare, arterial insufﬁciency
must be promptly investigated and treated appropriately.
Fig. 6. Echo presentation of Impella in position, (a) clinical image and (b) schematic drawing.
Table 2
Checklist upon arrival at the ICU.
• At arrival check that Tuohy-Borst valve on Impella catheter is locked.
• When patient has been installed in ICU perform echocardiography to ensure
optimal Impella position.
• Disable Autoﬂow feature on console and switch to P-level mode with as high
support as possible (P8). Disable suction control.
• Transfer the purge system to “standard conﬁguration”.
• Ensure that roller clap on pressure bag is open.
• Verify pressure bag pressure is 300–350 mm Hg.
• Secure Impella catheter to the inner aspect of patient's leg.
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Multiple studies have documented the low risk of signiﬁcant arterial
complications (similar to IABP) with Impella support when good access
management techniques were employed [7,41,42].
11. Device management in the CCU/ICU
11.1. Impella placement and position during long-term support
Accurate Impella placement is essential during all phases of Impella
support but it is particularly important for long term support. Correct
placement across the aortic valve is critical to avoid complications
including hemolysis, suction episodes and inadequate hemodynamic
support. Attention to the positioning of the device begins in the cathe-
terization laboratory or operating room by preventing migration into
the LV. This is best accomplished by removing excess slack from the
catheter in the ascending aorta or transverse aortic arch. With the
Impella set at P8 (high thrust condition) the excess slack is removed
so that the Impella catheter lies along the inner curve of the aorta and
that the positioning marker is approximately at the aortic valve. The
aim is to place the inlet approximately 3.5 cm distal to the aortic
valve. Care should be taken during insertion to avoid wire placement
in areas other than the LV apex, avoiding the subannular position or
any position that interferes with the anterior mitral leaﬂet or entrains
the catheter into the papillary muscles. Careful attention to positioning
alarms and to potential loss of position after patientmovement is critical
to success. To ensure proper positioning after transition to the ICU/CCU,
a close cooperation between trained ICU physicians, ICU nursing staff
and cardiologists with understanding of percutaneous circulatory
support is needed. It is recommended that upon arrival in the ICU a
check list is completed as listed in Table 2.
11.2. Echocardiography
Bedside echocardiography should be available on a 24 hour basis for
evaluation of placement with transthoracic (TTE) or transesophageal
echocardiography (TEE). Images obtained with TTE in the parasternal
long-axis view (Fig. 6) produce the optimal view. In this view, effort
should be made to identify the inlet of the device, ideally located in
the LV cavity approximately 3.5 cm from the aortic valve. The best TEE
study is usually obtained in the mid esophageal view with a 120–130
degree rotation. Manipulation of the catheter should be done during
continuous echocardiographic guidance since, due to “slack”, move-
ment of the catheter in the aorta does not necessarily translate into
the desired movement of the pump. Heavy turbulence with aliasing of
colors makes color ﬂowmapping difﬁcult to interpret, yet the “mosaic”
of colors associated with the outﬂow of the device should appear above
the aortic valve when Impella is properly positioned. Echocardiography
should also address right ventricular function (tricuspid annular excur-
sion) and volume status (size and respiratory variability in inferior vena
cava size) and should be performed amidst any suspicion of device
displacement.
11.3. Anticoagulation
Two separate and distinct anticoagulation solutions are required
during Impella support:
1. Systemic anticoagulation titrated using standard techniques and,
2. Anticoagulant added to the purge ﬂuid to prevent blood entrance into
the motor chamber and to maintain patency of the purge solution
channel. If the amount of UFH in the purge ﬂuid leads to undesired
systemic anticoagulant effects asmeasured byACTor PTT, the concen-
tration of UFH in the purge ﬂuid can be reduced.
The device is approved to be used with systemic anticoagulation,
with a suggested activated clotting time (ACT) of 160–180 s or locally
adjusted activated partial thrombin-time (aPTT) values with a target
ACT of 160–180 s. In most clinical situations, the purge heparin ﬂowing
at 4 to 8 cm3/h will not be sufﬁcient to achieve desired systemic
anticoagulation. In the case of (suspected) heparin induced thrombocy-
topenia (HIT), it is possible to replace both the anticoagulant in the
Table 4
Most common clinical complications.
Complications Frequency⁎ Symptoms Treatment
Access site bleeding 17.5% Bleeding including hematoma Local control/surgical repair
Access site infection Erythema, ﬂuctuance Drainage/antibiotics
Limb ischemia b4% Pain, pulselessness, paresthesia, pallor, paralysis Distal extra-anatomic bypass, thrombectomy
Hemolysis⁎⁎ b10% Hematuria Check device position
Stroke b2% Paralysis According to local protocol
⁎ Frequencies given for during long term support. Complications during elective high-risk procedures very low and comparable to IABP.
⁎⁎ Free hemoglobin N40 mg/dL.
Table 3
Most common console alarms.
Alarm condition Frequency Interpretation Clinical picture Treatment
Position wrong Common Inlet and outlet in the same chamber (both in
LV or both in AO)
May occur during the start-up phase and transportation Re-position under echo or
ﬂuoroscopic guidance
Position unknown Common Difference between max and min pressure on
aortic pressure curve b20 mm Hg.
Frequently due to low native heart pulsatility Re-position under echo or
ﬂuoroscopic guidance
Suction Common Above normal motor current necessary for set
performance level.
Reduction of ﬂow due to insufﬁcient volume
Device too deep or low volume status.
Frequently due to high resistance in Impella inﬂow
when in contact with LV wall or papillary muscle
Re-position under echo or
ﬂuoroscopic guidance
Low volume/Suction Common Flow lower as expected for set performance
level. Either due to suction or due to high
afterload.
May cause hemolysis if positioned wrong.
Check free hemoglobin (N40 mg/dl)
Optimize volume status.
RV failure?
High purge pressures Rare Increased pressure (N1100 mm Hg) at purge
system due to increase resistance anywhere
along the purge lumen necessary to prevent
blood entry in the motor compartment.
After long term support.
Catheter kink or blood ingress into motor.
May precede motor stop if extreme.
Place a new purge cassette when
longer support is needed.
Sudden pump stop Very rare Most likely clot ingestion. Possible systemic emboli. Exclude LV thrombus.
Adequate anticoagulation (ACT
180–200 s)
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purge ﬂuid and systemic anticoagulation by direct thrombin inhibitors
(DTI) such as Argatroban or Bivalirudin.
11.4. Weaning
Patients should be supported until hemodynamics are stable and no
more than a small dose of pharmacological inotropic support is
required. Initial screening for myocardial recovery can be accomplished
using short weaning trials during echocardiographic observation.
During ﬁnal weaning from Impella, the performance level is gradually
decreased over 4–6 h until support is at approximately 1–1.5 L/min.
Echocardiography is recommended to ensure recovery of LV function
and stability of cardiac index. The SVO2, lactate and arterial pH should
be monitored during the weaning period. Once the decision to explant
has been made, the catheter can be pulled back into the descending
aorta and the systemic UFH can be discontinued allowing the ACT to
fall into the ≤150 s range. After 30 min, the Impella can be turned off
and removed with subsequent manual compression (minimum
30 min) to achieve hemostasis.
11.5. Most common complications and console alarms
Complication rates are low and most complications are related
to bleeding mainly during longer usage. These complications require
careful patient selection where potential beneﬁt is higher compared to
increased risk of complications for speciﬁc patients as listed in Figs. 4
and 5. Most common console alarms and clinical complications are
depicted in Tables 3 and 4 and usually require individual decision
making.
12. Starting your Impella program
Once you have decided to begin an Impella or any advanced circula-
tory support program, there are several important points to consider.
First, make sure that all segments and stakeholders have access to
training from the beginning. This should include catheterization lab
personnel and administration, nurses and physicians from the ICU and
CCU, surgeons and operating room personnel, intensivists, and perfu-
sion services. Local protocol development is important and enables
uniform care regardless of which physician is on call.
Finally, we recommend that the ﬁrst cases undertaken in any
program should be elective high risk interventional cases (PCI) rather
than cardiogenic shock cases. Although there is a temptation to use
the system for patients in extremis, this increases the chances or errors
during insertion and repetitive use in such patientswith associatedpoor
outcomes can be demoralizing for the staff and may result in a high
perceived mortality rate for patients treated with any technology in
this situation. Elective high risk cases can be predicted with some
accuracy and will allow your mentors and clinical representatives to
be present. This allows reinforcement of training in a non-threatening
environment which is important with technology that is not used on a
daily basis. A PROTECT 2 trial subanalysis showed that a learning
curve however small does exist [43]. Supporting the elective high risk
procedures allows the staff to build conﬁdence in providing circulatory
support in the catheterization laboratory so that when the STEMI shock
patient arrives in the off hours, they are able to seamlessly provide the
required Impella and other supportive measures (Fig. 7).
13. Conclusion and summary
This report attempts to relate best practices with the Impella circula-
tory support system from a group of European experienced users of the
Impella device with some of the recommendations being applicable to
percutaneous mechanical support in general. Through collaboration
and professional review, we believe that the information compiled here-
in can offer the new center and physician useful and important best prac-
tices for use of the Impella system. An understanding of the device
variations, clinical application, and physiologic impact of device usage
as well as an understanding of the alarms and potential risks are all im-
portantwhen considering a patient for percutaneous circulatory support.
In the current absence of evidence based from randomized clinical
trials, this consensus group acknowledges that there are patients that
could beneﬁt from mechanical support and has aimed to guide clinical
usage with a set of recommendations based on a vast experience with
the Impella technology.
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Fig. 7. Preferred strategy to start an Impella program.
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